Organ specific tumor markers: What's new?

被引：24
作者：
Kannan Vaidyanathan
D. M. Vasudevan
机构：
[1] Department of Biochemistry, Amrita Institute of Medical Science, Kochi 682041, Kerala
来源：
Indian Journal of Clinical Biochemistry | 2012年 / 27卷 / 2期
关键词：
Immunohistochemical markers; Molecular markers; Proteomic markers;
D O I：
10.1007/s12291-011-0173-8
中图分类号：
学科分类号：
摘要：
Tumor markers are molecules produced in the body in response to cancer. An ideal tumor marker should have high sensitivity and specificity, should be cheap, and should be easily detected in body fluids. Identification of novel markers is important and it is expected that with the advent of newer technologies, more reliable markers will be discovered. This review discusses the currently available tumor markers for different malignancies. © 2012 Association of Clinical Biochemists of India.
引用
收藏
页码：110 / 120
页数：10
相关论文
共 76 条
[11]  
Bast Jr. R.C., Klug T.L., Schaetzl E., Lavin P., Niloff J.M., Greber T.F., Et al., Monitoring human ovarian carcinoma with a combination of CA 125, CA 19-9, and carcinoembryonic antigen, Am J Obstet Gynecol, 149, 5, pp. 553-559, (1984)
[12]  
Dawood M.Y., Ratnam S.S., Teoh E.S., Serum estradiol-17 beta and serum human chorionic gonadotropin in patients with hydatidi-form moles, Am J Obstet Gynecol, 119, 7, pp. 904-910, (1974)
[13]  
Yachnin S., The clinical significance of human alpha-fetoprotein, Ann Clin Lab Sci., 8, 2, pp. 84-90, (1978)
[14]  
Beveridge R.A., Review of clinical studies of CA 27.29 in breast cancer management, Int J Biol Markers., 14, 1, pp. 36-39, (1999)
[15]  
Lehner R., Enomoto T., McGregor J.A., Shroyer A.L., Haugen B.R., Pugazhenthi U., Et al., Quantitative analysis of telomerase htert mrna and telomerase activity in endometrioid adenocarcinoma and in normal endometrium, Gynecol Oncol, 84, 1, pp. 120-125, (2002)
[16]  
Mylonas I., Matsingou C., Kaufl S.D., Bruning A., Inhibin/activin betaE-subunit in uterine endometrioid adenocarcinoma and endometrial cancer cell lines: From immunohistochemistry to clinical testing?, Gynecol Oncol., 122, 1, pp. 132-140, (2011)
[17]  
Mylonas I., Inhibin-a subunit expression in uterine endometrioid adenocarcinomas and endometrial cancer cell lines: A potential prognostic factor, Int J Mol Med., 27, 3, pp. 309-318, (2011)
[18]  
Chang H.L., Pahlavan N., Halpern E.F., MacLaughlin D.T., Serum müllerian inhibiting substance/anti-müllerian hormone levels in patients with adult granulosa cell tumors directly correlate with aggregate tumor mass as determined by pathology or radiology, Gynecol Oncol., 114, 1, pp. 57-60, (2009)
[19]  
Holden J.A., Snow G.W., Perkins S.L., Jolles C.J., Kjeldsberg C.R., Immunohistochemical staining for DNA topoisomerase II in frozen and formalin-fixed paraffin-embedded human tissues, Mod Pathol., 7, 8, pp. 829-834, (1994)
[20]  
McIntosh M.W., Drescher C., Karlan B., Scholler N., Urban N., Hellstrom K.E., Et al., Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma, Gynecol Oncol., 95, 1, pp. 9-15, (2004)
12345678